$PODD

STONESIFER TIMOTHY C. purchased $400K of PODD

STONESIFER TIMOTHY C. purchased 2,790 shares of INSULET CORP (PODD) at $143.51 ($0.40M total) on 2026-06-03.

Original reporting
SEC EDGAR · STONESIFER TIMOTHY C.
Published Jun 4, 2026, 8:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PODD
Bullish
medium confidence
Mentioned
$PODD
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PODDBullishLow
01

Why it matters

Insider buying may slightly improve sentiment, but it does not change the company’s fundamentals or near-term earnings outlook based on the information provided.

02

Market read

Traders may note the insider purchase as a small positive sentiment datapoint, but it is unlikely to drive a durable repricing without accompanying fundamental news.

03

What to watch

The filing states no pre-arranged 10b5-1 plan; however, without context on prior trading patterns or motivations, signal strength remains uncertain.

Relevance 6/10Novelty 6/10Timing: Filed today; transaction dated 2026-06-03

Background

This is an SEC Form 4 insider transaction (director open-market purchase) for Insulet (PODD).

Company-level read

Ticker impact

$PODDBullishMedium confidence
Context

Insider director Timothy C. Stonesifer bought 2,790 shares of Insulet at $143.51/share via an open-market purchase disclosed on Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

Form 4 insider buys can be interpreted as confidence, but this is a routine disclosure without new operational/financial information or guidance changes.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Insider buys on Form 4 can reflect diversification, liquidity needs, or routine planned activity rather than a new bullish thesis.

Key entities

  • INSULET CORP

    Subject of the Form 4 insider transaction; director bought shares in an open-market purchase.

  • STONESIFER TIMOTHY C.

    Director who purchased 2,790 shares of PODD for ~$400.4K.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

$PODDMed

Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

Insulet PODD reports strong growth in Omnipod 5 AID system adoption, with Q2 2026 revenues up 23.8%. The company faces competition and macroeconomic pressures but has raised international growth guidance. PODD's earnings beat estimates for four straight quarters, with a 22.2% long-term growth rate. Management expects continued expansion and product development, including Omnipod 6 and a Type 2 system launch in 2027.

$PODDMed

Is Class Action Scrutiny Of Omnipod Controls Altering The Investment Case For Insulet (PODD)?

Insulet (PODD) faces class action lawsuits alleging false statements about manufacturing controls and safety risks in its insulin delivery products. The lawsuits, filed by Robbins Geller and Rosen Law Firm, cover shares bought between February 2025 and May 2026. Insulet maintains revenue growth guidance of 21-23% for 2026 despite recent recalls affecting 7 million units. Analysts project varying revenue and earnings estimates for 2029, with growth potential but increased risks due to manufacturi

$PODDMedAI 8/10

Insulet (PODD) Q2 2026 Earnings Call Transcript

Insulet (PODD) reported Q2 2026 revenue of $801.7M, up 22.7% constant currency and above guidance. Adjusted EPS was $1.66, up 41.5%. U.S. Omnipod revenue was $544.1M, and international was $251.8M. Management revised U.S. full-year Omnipod growth to 17% to 19% and raised international to 30% to 32%, citing weaker type 2 retention.